Fundación Caubet-Cimera Centro Internacional de Medicina Respiratoria Avanzada, Bunyola, Spain.
Área Hospitalaria de Valme, Sevilla, Spain.
Chest. 2013 Mar;143(3):694-702. doi: 10.1378/chest.12-1053.
The new Global Initiative for Chronic Obstructive Lung Disease (GOLD) update includes airflow limitation, history of COPD exacerbations, and symptoms to classify and grade COPD severity. We aimed to determine their distribution in 11 well-defined COPD cohorts and their prognostic validity up to 10 years to predict time to death.
Spirometry in all 11 cohorts was postbronchodilator. Survival analysis and C statistics were used to compare the two GOLD systems by varying time points.
Of 3,633 patients, 1,064 (33.6%) were in new GOLD patient group A (low risk, less symptoms), 515 (16.3%) were B (low risk, more symptoms), 561 (17.7%) were C (high risk, less symptoms), and 1,023 (32.3%) were D (high risk, more symptoms). There was great heterogeneity of this distribution within the cohorts ( x (2) , P < .01). No differences were seen in the C statistics of old vs new GOLD grading to predict mortality at 1 year (0.635 vs 0.639, P = .53), at 3 years (0.637 vs 0.645, P = .21), or at 10 years (0.639 vs 0.642, P = .76).
The new GOLD grading produces an uneven split of the COPD population, one third each in A and D patient groups, and its prognostic validity to predict time to death is no different than the old GOLD staging based in spirometry only.
新的全球倡议慢性阻塞性肺疾病(GOLD)更新包括气流受限、COPD 加重史和症状,以对 COPD 严重程度进行分类和分级。我们旨在确定这 11 个明确的 COPD 队列中的分布情况,并对其进行预测,直到 10 年内死亡的预后有效性。
所有 11 个队列的肺活量测定均为支气管扩张剂后。生存分析和 C 统计用于比较两种 GOLD 系统,通过改变时间点进行比较。
在 3633 名患者中,1064 名(33.6%)属于新 GOLD 患者组 A(低风险,症状较轻),515 名(16.3%)属于 B 组(低风险,症状较多),561 名(17.7%)属于 C 组(高风险,症状较轻),1023 名(32.3%)属于 D 组(高风险,症状较多)。在队列中,这种分布存在很大的异质性(x2,P<.01)。旧 GOLD 分级与新 GOLD 分级在预测 1 年死亡率(0.635 与 0.639,P=0.53)、3 年死亡率(0.637 与 0.645,P=0.21)或 10 年死亡率(0.639 与 0.642,P=0.76)方面没有差异。
新的 GOLD 分级对 COPD 人群进行了不均匀的划分,A 组和 D 组各占三分之一,其预测死亡时间的预后有效性与仅基于肺活量测定的旧 GOLD 分期没有区别。